Recipharm Signs Agreement to Manufacture Liproca Depot

December 17, 2015
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management

Volume 12, Issue 1

Recipharm has signed an agreement with Sweddish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.

Recipharm announced that it has signed an agreement with Swedish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.

The patented technology, Liproca depot, is a novel bioresorbable, biocompatible, and locally injectable modified-release formulation of 2-hydroxyflutamid, prepared as a paste, prior to injection, and which cures shortly after injection. The product is delivered in a prefilled syringe, which also serves as mixing equipment of the paste prior to injection.

This agreement marks an important step in the preparation of a Phase IIb study of Liproca depot, which is expected to begin in 2016. In connection with the agreement, Recipharm has invested SEK 5 million in a private placement, making it the third largest shareholder of LIDDS.

Source: Recipharm